Biotech makes a $303M run on Wall Street; Bil­lion­aire Thiel backs a start­up round for an­tibi­ot­ic de­vel­op­er

⇨  It’s been an­oth­er big week on the biotech IPO front. De­ci­phera $DCPH went pub­lic, rais­ing $128 mil­lion for its sol­id tu­mor work, stick­ing to the top of the range at $17 a share. The UK’s Night­star Ther­a­peu­tics $NITE team — a gene ther­a­py com­pa­ny — hit the mid­dle of the range, rais­ing $75 mil­lion at $14 a share. And Nu­Cana, an­oth­er UK biotech which jumped to Nas­daq, scored a cool $100 mil­lion from its IPO. Nu­Cana says it is work­ing on next-gen chemother­a­pies. Add it all up and you have a pic­ture of a thriv­ing biotech mar­ket, which is cer­tain to at­tract more S-1s as the in­dus­try en­joys an­oth­er up­beat run of new of­fer­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER